Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk
BMC Pulmonary Medicine volume 14, Article number: 77 (2014)
A gene-based estimate of lung cancer risk in smokers has been shown to act as a smoking cessation motivator in hospital recruited subjects. The objective of this trial is to determine if this motivator is as effective in subjects recruited from an NHS primary care unit.
Subjects will be recruited by mailings using smoking entries on the GP electronic data-base (total practice population = 32,048) to identify smokers who may want to quit. Smoking cessation clinics based on medical centre premises will run for eight weeks. Clinics will be randomised to have the gene-based test for estimation of lung cancer risk or to act as controls groups. The primary endpoint will be smoking cessation at eight weeks and six months. Secondary outcomes will include ranking of the gene-based test with other smoking cessation motivators.
The results will inform as to whether the gene-based test is both effective as motivator and acceptable to subjects recruited from primary care.
Registered with Clinical Trials.gov, Registration number: NCT01176383.
Gene testing in primary care is no longer limited by their exorbitant cost. The prices of genetic tests are dropping faster than Moore’s law for computing costs . This leads the focus to shift from cost of genetic testing to the clinical value of individual gene tests. The recent development of gene-based tests that predicts the risk of lung cancer in smokers is an important example .
Despite the well accepted 10-15% probability of lung cancer in smokers, 50% of smokers do not believe they are at significantly increased risk . However, over 80% of smokers would like to know their personal risk of lung cancer . There is a plausible three way link between biomarkers for chronic obstructive pulmonary disease (COPD), a set of 20 single nucleotide polymorphisms (SNPs) associated with cancer risk and lung cancer [5–8] (Figure 1). Research has shown a strong association between a high lung cancer susceptibility score derived from family history of cancer, the 20 SNPs, COPD history (Auckland formula) and the development of lung cancers whereas healthy smokers matched for age, gender and lifetime smoking habits had a relatively low score (n = 446 lung cancer subjects, 484 healthy current smokers). The odds ratio for lung cancer risk varied from 0.2-3.2 depending on the genetic risk (p < 0.001) [9, 10]. The accuracy of the Auckland formula in estimating lung cancer risk for a score of >4 was: sensitivity 90%, specificity 45% (Figure 1 which also includes scores for 52 subjects who developed cancer from a six year prospective study of 1212 smokers and ex-smokers). The score for prediction of non-cancer was conducted with a follow up of just six years. It means that 45% of non-cancer subjects have a low cancer score and 55% have some degree of increased score. The 55% with increased scores have simply not been followed up long enough for lung cancers to develop yet. Notwithstanding this limitation there is now a 20 SNP gene test for prediction of lung cancer in smokers under the trade name Respiragene.
Two case-control studies showed a 5-10% increase in cessation with a single gene test of small effect [11, 12]. A small smoking cessation pilot study using spirometry results and explanations using the Fletcher-Peto diagram to explain risk demonstrated that patients find this is an acceptable method and the quit rate at 12 months was 27% . In a randomised control trial patients were given either a full explanation of the results of spirometry testing, including an estimation of lung age or just their forced expiratory volume in the first second (FEV1), without explanation (control group). The group of patients who were given the full explanation had a 7.2% higher quit rate than the control group . Data from a hospital outpatient cohort in Auckland suggest a larger increase in quit rate with Respiragene test and the Auckland formula (Table 1). Subjects, who were current smokers in the pre-contemplative and contemplative stage, were randomised into either the test group or control group and only the test group had the Respiragene test. Counselling and follow-up was done by telephone. Using Auckland formula to incorporate the results of the Respiragene test, clinical data and family history a score ranging 1-12 with associated risk level (moderate risk, high risk, very high risk) was calculated and explained to test subjects. Neither group were involved in any formal smoking cessation programme. Indeed, of the 13 subjects that had managed to stop smoking, (28% of the gene-tested group), 48% quit without any medical assistance and only 52% had nicotine replacement therapy [15, 16]. When compared with previous studies using telephone counselling alone  (Figure 2), there is a 20-25% improvement in smoking cessation with the Respiragene test (Table 1). The improvement in intention to quit increases from 56% before testing to 67% in smokers with an average smokers risk of lung cancer or 89% in smokers with a high risk of lung cancer .
A large hospital trial using Respiragene for calculating lung cancer susceptibility is currently underway in the USA , but there are no planned UK investigations. This study fills that gap and uses the NHS framework for smoking cessation. Other studies have taken place looking at how lung functioning testing in COPD might motivate smokers to quit, suggesting that it is feasible to conduct this sort of study [13, 14, 20]. This protocol describes a trial to evaluate a gene-based risk test (using genetic and clinical data) as a smoking cessation motivator, in smokers wishing to participate in an NHS primary care smoking cessation clinic (in the action stage of change), alongside the usual counselling and prescribing protocol. It will differ from previous studies using gene testing as a motivator, however, in that the NHS primary care counselling and prescribing protocol will include several other motivators (CO breath testing, saliva cotinine testing and intensive counselling) whereas the Auckland trial, using the same gene test, had none of these. Also, the method of recruitment will differ in that primary care subjects will, of necessity, be different from the Auckland hospital outpatient cohort [15, 16].
Can the Respiragene test combined with an estimation of lung cancer susceptibility be used to increase the uptake, adherence to and success rate in an established smoking cessation programme in subjects who want to quit in a National Health Service, United Kingdom (NHS UK) setting?
Genetic testing and estimation of lung cancer susceptibility should increase “smoking cessation outcomes” at six months to >30% (or 1.5-2 fold greater than usual care) irrespective of the risk scores assigned to subjects .
This protocol has been approved by Surrey Research Ethics Committee at the Royal Surrey County Hospital, Guildford, Surrey, UK.
A number of focus groups of different aged smokers will be held to enable them to contribute to the design of the study
Subjects will be recruited from a large general practice in Surrey (practice population= > 30,000). Smokers aged 20-70 years will be identified from the practice records and contacted by post by their GP. Patients who reply stating that they wish to stop smoking will be randomised (stratified randomisation to ensure equivalent age and gender mix) to two clinics (Figure 3) only one of which will include the gene-based test. Previous trials of genetic testing in association with smoking cessation achieved 83-100% of participants opting for the test depending on the method of recruitment [8, 21]. There will be two mailings with SAEs for recruitment with the aim of recruiting at least 30 subjects per clinic (see Power calculations under heading “statistics”). In the first letter the patient’s GP asks the patient to give permission for the researcher to contact him/her to ask about taking part in smoking cessation research (with possible genetic risk testing) and encloses fact sheet 1 and a stamped addressed envelope (SAE) for reply.
Mailing 2. The principal investigator mails patient with Letter 2 to ask him/her if they would like to attend an 8-week smoking cessation clinic and asks if they would be willing to have a test for genetic susceptibility to development of lung cancer and encloses SAE for reply.
Mailing 3. The principal investigator mails Group B subjects and Group A test-concordant subjects to confirm dates of the smoking cessation sessions and full patient information leaflet and consent form enclosed. The information sheet will be slightly different for group A and B. Non-test concordant subjects within group A will be invited to attend the practice nurse for smoking cessation.
3/Inclusion and exclusion criteria
Inclusion criteria: Aged 20-70 years, smoking more than 10 cigarettes daily.
Exclusion criteria: Aged under 20 years or over 70 years, smoking less than 10 cigarettes daily, history of major depression and other psychiatric conditions, dementias and serious or terminal illness (cancers etc.). Patients on warfarin would be excluded due to interactions between warfarin and varenicline as varenicline will be used as the modern treatment of choice for smoking cessation. Patients who smoke less than 10 cigarettes/day and patients who did not wish to have a genetic test or do not wish to take part in a research study will be referred to the practice nurse for smoking cessation.
4/Smoking cessation clinics
For group A subjects, only subjects who have expressed an interest in having a genetic test and gene-based estimation of susceptibility to lung cancer in mailing 2 will be invited to participate (see referral for decliners above). For group B subjects, all subjects willing to participate are invited to do so. Uptake into smoking cessation programme (i.e. proportion of invitees who accept invitation and attend clinic of those mailed invitation) will be recorded. All subjects who attend the first session of the research clinic will be asked by the principal investigator, JN, to sign a consent form and will be invited to raise any concerns about the protocol (as explained in the full information sheet). The consent form will then be countersigned by JN.
Group A clinics and Group B clinics will be held on different weekdays at the same health centre premises.
Test Subjects who attend Clinic A will be offered a fact sheet on the health risks of smoking (including lung cancer) and the option of the gene-based test for calculation of lung cancer susceptibility whilst subjects who attend Clinic B will be given the same fact sheet on the health risks of smoking (including lung cancer) but without any reference to the gene-based test. The principal investigator will be responsible for handing out the fact sheets and administering the gene-based test in Clinic A and for handing out and explaining the fact sheet in Clinic B.
NHS Surrey’s Smoking Cessation Practitioners will lead in-house smoking cessation clinics A and B using the NHS smoking cessation guidelines  under the supervision of the principal investigator at the medical centre. There will be:
Introductory session which includes a new near patient test for salivary cotinine (nicotine metabolite) – trade name SmokeScreen .
At session 2, patients will be given advice on therapies for smoking cessation. We expect that most patients will opt for a course of varenicline and they will be advised to contact their GP for a prescription.
This is followed by seven more weekly sessions and a follow-up session at six months (Figure 4). Uptake and adherence to smoking cessation will be monitored by weekly carbon monoxide exhalation measurements (breath test). The principal investigator will be involved in clinic A administering the gene-based test and determining if subjects have COPD from practice records and history in session 1. Participants who are heavy smokers, have a smokers cough and use a salbutamol inhaler can be judged to have COPD even if this is not entered in their GP records (all Group A & B subjects will have spirometry at their 6-month follow-up). Subsequently the principal investigator will report back to clinic A patients with estimated lung cancer risks (session 3). To ensure balance in the control clinic the principal investigator will also attend Clinic B sessions 2 and 3 (see Figure 5 flow charts).
At the eight week clinic and the 6-month follow-up clinic smoking cessation status and carbon monoxide breath test score will be recorded and a feedback questionnaire used to assess efficacy of various components will be administered.
Mailing 4. Telephone calls followed by letters to patients with invitation to 6-month follow-up session with NHS Smoking Cessation Practitioners and the principal investigator when cessation rate will be assessed and verified by repeating the carbon monoxide breath and salivary cotinine tests.
for further details see Figure 5: flow charts
We anticipate good attendance at the eight week free smoking cessation clinic, as would be expected if it were a regular NHS smoking cessation clinic but the attendance at the 6-month follow-up clinic may be more challenging. We consider this attendance essential and as attendance will take up an evening of their time, study participants should be paid for their travel expenses (£20) and will receive up to three reminders. Group B subjects attending at the 6-month follow up who have been unable to quit will be offered the gene-based test at this stage.
Technique for taking the respiragene test
The test requires a Buccal swab and the subjects should not eat or drink within 15 minutes prior to supplying a sample (if has eaten or taken a drink within 15 minutes then rinse mouth with tap water). The nurse taking the sample should wear latex or plastic gloves and take care to avoid contact with the buccal swab collection tip to avoid DNA (deoxyribonucleic acid) contamination. Then:
Open buccal swab package at the handle end and carefully remove the swab.
Holding handle end of swab stick, scrape the collection tip firmly against the inside of the cheek 5-6 times (about 10 seconds), being careful not to press the plunger that ejects the tip.
After taking the sample, eject the swab tip into a labelled 2 ml microcentrifuge tube by firmly pressing the plunger at the end of the handle.
Complete and affix the sample tube label onto the microtube. The sample label requires the anonymised trial code for the subject.
Storage of the respiragene test
After sample collection, tips can be kept at room temperature if they are posted immediately. If storage is necessary, freeze the tubes containing the tips at -20°C.
Packaging instructions for return of samples to Lab21 Ltd
Place absorbent material around the tube and then place tube in the plastic bag provided with the kit. Seal the plastic back as per the instructions on the bag
Place the plastic bag containing the sample tube into the shipping box.
Seal the box with the security seal supplied.
Using the Freepost service provided, send the samples to: Lab 21, 184 Cambridge Science Park, Cambridge CB4 0GA.
Patients will be asked to sign a disclaimer form that explains clearly that this test can only give an estimation of cancer risk and is a test that is still under development (one copy of form for investigators and one for patient).
Interpretation of result of respiragene test
Lung cancer susceptibility is calculated using the Respiragene test Auckland formula :
Lung cancer score = (number of susceptible genotypes) - (number of protective genotypes) + 3 (for positive family history) + 4 (for past history of COPD) + 4 (for age > 60 years old).
The laboratory reports include the scores with an explanation of how the scores relate to a risk category (see Table 1). When the subject is aged <60 years, the report will also include the score and risk category that would apply if the subject is still a smoker at age 60 years or over.
The questionnaires will be slightly different for groups A (questionnaire 2a) and B (questionnaire 2b) as only 2a will contain a direct reference to the gene-based test. Patients who fail to attend at eight weeks and six months will be contacted by telephone to remind them to complete their questionnaires and hand them in to the practice manager. They are designed to determine which subjects have quit smoking or cut down and which subjects who have failed to quit still plan to do so. There is a section that asks about general motivators and components of the smoking cessation programme. The subjects will be asked to score these motivators and smoking cessation aids for their efficacy in helping them to quit. The questions in this section are almost identical to a validated questionnaire . There are also further questions on whether the subject would recommend the Respiragene test to a relative or friend and an open ended question for subjects to add their own comments about the concept of a test that predicts susceptibility to lung cancer in a smoker.
Data quality assurance
The study has been designed and will be reported in accordance with CONSORT (Consolidated Statement of Reporting Trials) . Data will be controlled in accordance with data protection legislation, institutional protocols of Sussex NHS Research Consortium, and NHS policies for research and information governance for ensuring patient confidentiality . Data will be analysed in SPSS (Statistical Package for Social Sciences) version 15 using an intention to treat approach.
Comparison of smoking cessation rates (7 day point abstinence and continuous abstinence) in Clinic A and Clinic B at 8 weeks and six months.
Number of smokers still smoking who state that they still plan to stop.
Daily cigarette consumption of those still smoking.
Mean scores for ranking of smoking cessation aids (gene-based test - Clinic A only, salivary cotinine, lung cancer facts - controls in Clinic B only and general counselling from NHS smoking counsellors).
Analyse questions about whether subjects would recommend the test to a member of family or a friend.
Analyse last (open ended) question using qualitative research methodology.
Primary end point
The difference between smoking cessation between Clinic A and Clinic B will be estimated from the four week and six month follow up for the primary endpoint (smoking status confirmed by carbon monoxide breathalyser and salivary cotinine tests). If there is the expected higher rate of smoking cessation for Clinic A compared with Clinic B, statistical significance will be demonstrated by the χ2 test.
Since there are, as yet, no case-control studies that compare quit rate following the gene-based test versus quit rate without the test, the expected difference in quit rate between Clinic A and Clinic B is difficult to estimate. Two case-control studies showing only a 5-10% increase in smoking cessation involved just a single gene of small effect [11, 12]. In a randomised control trial patients were given either a full explanation of the results of spirometry testing, including an estimation of lung age or just the FEV1, without explanation (control group). The group of patients who were given the full explanation had a 7.2% higher quit rate than the control group. However, data from Auckland suggest a larger uplift of quit rate with Respiragene. This can be explained by the superior predictive power of a 20-gene test combined with clinical history (personal history of COPD and family history of lung cancer) to give a rather more impressive estimate of cancer risk than anything previously available.
The adequacy of sample size was tested using data from smoking cessation trials that showed:
A 48% quit rate at 2-4 weeks in subjects with high and very high lung cancer risk scores but this difference shrinks to 27% at 6 months.
Therefore, with a minimum sample sizes of 30 per group the following calculations based on these estimated quit rates apply (Table 2). Statistical power of 87.1% is generally acceptable for publication (for alpha error of 5% - i.e. 5% probability of incorrectly rejecting the null hypothesis that there is no difference in the percentage values). For further detailed statistical analysis, refer to Additional file 1.
Secondary outcome measures
Similarly, the significance of secondary endpoints on intention to stop smoking, cigarette consumption, uptake of invitation to cessation, adherence to cessation course and self-reported smoking cessation will be calculated by the χ2 test but the p value for the ranking scores for information on lung cancer risk and other smoking cessation aids and motivators will be estimated from the unpaired student t-test.
The open ended question: “How do you feel now about having had a genetic test that estimates the probability that you will develop lung cancer at some future date?” will have to be analysed by qualitative analysis to determine the main recurrent themes in responses.
Smoking cessation is one of the most cost effective interventions that can be achieved in primary care . However many smokers are very reluctant to commit to a smoking cessation programme (precontemplative and contemplative) and about half of those that attend for smoking cessation intervention (action stage of change) are likely to drop out or give up trying. Therefore, any methodology that increases motivation in both unmotivated and motivated smokers could be very valuable. The gene-based test we are offering has shown promise as a smoking cessation motivator in precontemplative-contemplative smokers in a hospital outpatient setting [15, 18] and now needs to be tested out as a motivator for improving adherence in a primary care smoking cessation clinic using a randomised controlled study.
The main strengths of this study are that it is being carried out on subjects from a large primary care population and should therefore be more representative of the general population than previous studies recruited from hospital patients and other special groups. We also have the advantage of being able to carry out this research within the established framework of the local stop smoking service.
Limitations and assumptions
Although we have estimated, based on previous smoking cessation work using this gene-based test, that the primary endpoint will show that having the test improves quit rate by 20-25%, this was based on a cohort of hospital outpatients in Auckland, New Zealand and subjects recruited from primary care may respond differently. Although we plan to recruit a minimum of 60 subjects, this may not be enough to balance unexpected and unknown confounding factors.
What we might find
We aim to recruit a minimum of 60 subjects to randomise 30 into group A (test group) and 30 into Group B (control group). The normal experience in NHS smoking cessation clinics is a drop-out rate of 40-50% [30–32]. We need, therefore, to attempt to recruit about 120 subjects in order to get a statistically significant result, based on the assumptions in our power calculations. We may, however, have underestimated the 6-month quit rate using the NHS local stop smoking guidelines  which typically involves a multi-interventional programme which includes combinations of varenicline prescriptions, breath carbon monoxide monitoring and intensive counselling giving a quit rate of 70-80% at 6-weeks.There are however no Surrey data for 6-month quit rate which we assume, on the basis of similar smoking cessation data to be about half the 6-week figure  ≅ 35%.
An unknown and unpredictable factor, that could skew results significantly, is the possibility that our multi-interventional approach could help to reinforce the health risk message equally for subjects in both groups. Also, the Auckland study design involved recruitment of precontemplative-contemplative smokers from a hospital outpatient setting, compared to this study that will involve primary care subjects who have volunteered to participate in a smoking cessation programme (ie smokers in the action stage of quitting). This population, therefore, could be sufficiently different to give unexpected results. However, the results of this trial will inform as to the acceptability of this approach as well as its effectiveness.
PG is a Visiting Professor of Primary Care at The University of Surrey. SdeL is Professor of Health Care and Clinical Informatics at The University of Surrey. JN is a primary care physician and visiting research fellow at The University of Surrey. WK is a visiting research fellow at The University of Surrey and an experienced smoking cessation nurse. PW is a Statistics Consultant in the Department of Mathematics at The University of Surrey.
Consolidated statement of reporting trials
Chronic obstructive pulmonary disease
National health service UK
Single nucleotide polymorphism
Stamped addresses envelope.
Wetterstrand KA, DNA Sequencing Costs: Data from the NHGRI Large-Scale Genome Sequencing Program. http://en.wikipedia.org/wiki/Personal_genomics#cite_note-18,
Smerecnik C, Grispen JEJ, Quaak M: Effectiveness of testing for genetic susceptibility to smoking-related diseases on smoking cessation outcomes: a systematic review and meta-analysis. Tob Control. 2012, 21 (3): 347-354. 10.1136/tc.2011.042739.
Smith SM, Campbell MC, Macleod U: Factors contributing to the time taken to consult with symptoms of lung cancer: a cross sectional study. Thorax. 2009, 64: 1953-531.
Sanderson SC, O’Neill SC, White DB, Bepler G, Bastian L, Lipkus IM, McBride CM: Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev. 2009, 18 (7): 1953-1961. 10.1158/1055-9965.EPI-08-0620.
Young RP, Hopkins R, Black PN, Eddy C, Wu L, Gamble GD, Mills GD, Garrett JE, Eaton TE, Rees MI: Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax. 2006, 61 (5): 394-399. 10.1136/thx.2005.048512.
Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD: COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009, 34 (2): 380-386. 10.1183/09031936.00144208.
Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD: Lung cancer susceptibility model based on age, family history and genetic variants. PLoS ONE [Electronic Resource]. 2009, 4 (4): e5302-10.1371/journal.pone.0005302.
Young RP, Hopkins RJ, Hay BA, Gamble GD: GWAS And Candidate SNPs For COPD And Lung Cancer Combine To Identify Lung Cancer Susceptibility: Validation In A Prospective Study. Am J Respir Crit Care Med. 2010, 181: A3738-
Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, Gardner HD, Sullivan R, Gamble GD: A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J. 2009, 85: 515-524. 10.1136/pgmj.2008.077107.
Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, Gamble GD: Lung cancer gene associated with COPD: triple whammy or possible confounding effect?. Eur Respir J. 2008, 32 (5): 1158-1164. 10.1183/09031936.00093908.
McBride CM, Bepler G, Lipkus IM, Lyna P, Samsa G, Albright J, Datta S, Rimer BK: Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev. 2002, 11 (6): 521-528.
Sanderson SC, Humphries SE, Hubbart C, Hughes E, Jarvis MJ, Wardle J: Psychological and Behavioural Impact of Genetic Testing Smokers for Lung Cancer Risk: A Phase II Exploratory Trial. J Health Psychol. 2008, 13: 481-494. 10.1177/1359105308088519.
Wells S, de Lusignan S: Does screening for loss of lung function help smokers give up?. Br J Nurs. 2003, 12 (12): 744-750.
Parkes G, Greenhalgh T, Griffin M, Dent R: Effect on smoking quit rate of telling patients their lung age: The Step2quit randomised control trial. BMJ. 2008, 336: 598-600. 10.1136/bmj.39503.582396.25.
Hopkins RJ, Young RP, Hay B, Gamble GD: Lung cancer risk testing enhances NRT uptake and quit rates in randomly recruited smokers offered a gene based risk test. Am J Respir Crit Care Med. 2012, 185: A2590-
Hopkins RJ, Young RP, Hay B, Gamble GD: Gene-based lung cancer risk score triggers smoking cessation in randomly recruited smokers. Am J Respir Crit Care Med. 2011, 183: A5441-
West R, Shiffman S, McLean D: Fast Facts: Smoking Cessation (Fast Facts series) – Paperback. 2007, London: Health Press
Young RP, Hopkins RJ, Smith M, Hogarth DK: Smoking cessation: the potential role of risk assessment tools as motivational triggers [Review]. Postgrad Med J. 2010, 86 (1011): 26-33. 10.1136/pgmj.2009.084947.
Cabebe E: Recruitment details: REACT Clinical Trial Lung Cancer Detection Study. http://www.elcaminohospital.org/Cancer_Center/Clinical_Trials/Lung_Cancer_Detection_Study,
McClure JB, Ludman EJ, Grothaus L, Pabiniak C, Richards J: Impact of spirometry feedback and brief motivational counseling on long-term smoking outcomes: a comparison of smokers with and without lung impairment. Patient Education & Counseling. 2010, 80 (2): 280-283. 10.1016/j.pec.2009.11.002.
Sanderson SK, Humphries SE, Hubbart C: Psychological and behavioural impact of genetic testing smokers for lung cancer risk. J Health Psychol. 2010, 13 (4): 481-494.
Croghan E: NHS Local stop smoking services, services delivery and monitoring guidance 2011/12. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213755/dh_125939.pdf,
Barnfather KD, Cope GF, Chapple IL: Effect of incorporating a 10 minute point of care test for salivary nicotine metabolites into a general practice based smoking cessation programme: randomised controlled trial. BMJ. 2005, 331: 999-10.1136/bmj.38621.463900.7C.
West R: Smoking toolkit study: protocol and methods. 2006, http://www.smokinginengland.info/sts-documents/ (ST5001)
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c869-10.1136/bmj.c869.
DH/IPU/Patient Confidentiality: Department of Health: Confidentiality – NHS Code of practice. 2003, http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4069254.pdf,
Lee JH, Jones PG, Bybee K, O’Keefe JH: A longer course of varenicline therapy improves smoking cessation rates [Review]. Prev Cardiol. 2008, 11 (4): 210-214. 10.1111/j.1751-7141.2008.00003.x.
West R, Sohal T: “Catastrophic” pathways to smoking cessation: findings from national survey. BMJ. 2006, 332: 458-460. 10.1136/bmj.38723.573866.AE.
Kahenda JW, Loomis BR, Anhikara B, Marshall L: A review of economic evaluations of tobacco control programs. Int J Environ Res Public Health. 2009, 6 (1): 51-68.
Sanders D, Fowler G, Mant D, Fuller A, Jones L, Marzillier J: Randomized controlled trial of anti-smoking advice by nurses in general practice. J R Coll Gen Pract. 1989, 39 (324): 273-276.
Wennike P, Danielsson T, Björn B, Westin A, Tøneson P: Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003, 98 (10): 1395-1402. 10.1046/j.1360-0443.2003.00489.x.
MacPherson L, Stipelman BA, Duplinsky M, Lejuez CW: Distress tolerance and pre-smoking treatment attrition: examination of moderating relationships. Addict Behaviour. 2008, 33 (11): 1385-1393. 10.1016/j.addbeh.2008.07.001.
Soulier-Parmeggiani L, Griscom S, Bongard O, Avvanzino R, Bounameaux H: One-year results of a smoking-cessation programme. Journal Suisse de Médecine. 1999, 129 (10): 395-398.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/14/77/prepub
We are grateful for the help of Aino Telaranta-Keerie and the staff of Lab 21 for their support and for carrying out the Respiragene tests. We are also indebted to Kevin Murphy of Synergenz for his encouragement and support. Professor Robert Young, and his team, of Auckland, New Zealand developed the Respiragene test and the risk score formula. His advice and guidance has been invaluable.
JN and PG are in receipt of research grants from Lab 21, Cambridge who are marketing the Respiragene test in the UK and Synergenz Bioscience Ltd. who financed the development of the test from its origins in New Zealand. We initially purchased SmokeScreen kits (for salivary cotinine estimation) from GFC Diagnostics Ltd. But they subsequently supplied 30 kits free of charge.
JN and PG developed the idea of a control trial of the Respiragene test after discussions with Aino Telaranta-Keerie of Lab 21, Cambridge. WK was involved in helping to write the protocol and her experience in running smoking cessation clinics was very helpful. PW was our statistical adviser and SdeL helped us to write the protocol in accordance with CONSORT principles and in development of trial methodology. All authors read and approved the final manuscript.
Electronic supplementary material
About this article
Cite this article
Nichols, J.A., Grob, P., de Lusignan, S. et al. Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk. BMC Pulm Med 14, 77 (2014). https://doi.org/10.1186/1471-2466-14-77